Belimumab (GSK1550188) · Benlysta
Monoclonal antibody
Evidence outlook
Approved: Systemic Lupus Erythematosus, Lupus Nephritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Systemic Sclerosis-Associated Interstitial Lung Disease
Also approved (2)
- Treatment of systemic lupus erythematosus in patients who have not responded sufficiently to conventional treatments
- Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti‑dsDNA and low complement) despite standard therapy. Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis. Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01381536 NCT01381536 · Systemic Lupus Erythematosus This Phase 1 study in 12 Japanese patients with SLE gave a single dose of belimumab (1 mg/kg or 10 mg/kg) or placebo, with participants masked. It was designed to characterize safety and drug levels, not to test efficacy, so it carries little weight as efficacy evidence. The registry lists one arm, but the publication reports a placebo group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT01381536 | 1 | To evaluate the safety, tolerability (For 84 days) 2010-11-27 | Belimumab 1 mg/kg and 10 mg/kg demonstrated a favorable clinical safety and tolerability profile in Japanese patients with SLE. The incidence of adverse events was similar across arms, with seven patients reporting at least one adverse event: three in the placebo group and two in each belimumab group. The single-dose pharmacokinetic profile was approximately dose proportional, with a long terminal elimination half-life (12.4-15.7 days), low clearance (3.55-4.65 mL/day/kg) and a small volume of distribution (76.2-80.1 mL/kg). | Weak signal | link ↗ |
View 7 more trials
BLISS-52 NCT00424476 · Systemic Lupus Erythematosus The trial was randomized, double-blind, and placebo-controlled, with 865 participants and a validated clinical disease-activity response as its primary endpoint. The primary endpoint was met for both belimumab 10 mg/kg (57.6% vs 43.6% placebo; p=0.0006) and 1 mg/kg (51.4% vs 43.6%; p=0.0129). Registry: NCT00424476 | 3 | SLE Responder Index (SRI) Response Rate at Week 52 (Baseline, 52 weeks) 2009-05 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
BLISS-SC NCT01484496 · Systemic Lupus Erythematosus This was a randomized, double-blind, placebo-controlled trial with 839 randomized participants. The clinical primary endpoint, SLE Responder Index response at Week 52, was significantly higher with belimumab than placebo (61.4% vs 48.4%; p=0.0006), supporting a strong evidence grade. Registry: NCT01484496 | 3 | Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52 2015-02-13 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
BLISS-76 NCT00410384 · Systemic Lupus Erythematosus This Phase 3 trial randomly assigned 819 people with systemic lupus erythematosus to belimumab 1 mg/kg, belimumab 10 mg/kg or placebo, with participants and investigators both unaware of assignment. The registry names its own primary analysis as the 10 mg/kg comparison against placebo on the SLE Responder Index at week 52, and that comparison was statistically significant (43.2% versus 33.5%, odds ratio 1.54, 95% CI 1.08 to 2.19, p=0.0167). The 1 mg/kg dose was tested only after that result was established and did not reach significance (p=0.0889). Registry: NCT00410384 | 3 | SLE Responder Index (SRI) Response Rate at Week 52 (Baseline, 52 Weeks) 2009-09 | SRI response at Week 52: 43.2% with belimumab 10 mg/kg vs 33.5% with placebo (p=0.0167); 40.6% with belimumab 1 mg/kg vs 33.5% with placebo (p=0.0889). | Partial signal | link ↗ |
BLISS-LN NCT01639339 · Lupus Nephritis The study randomly assigned 448 participants to belimumab or placebo, used quadruple blinding, and maintained standard therapy in both groups. The hard clinical renal-response endpoint was met at Week 104: 43.0% responded with belimumab versus 32.3% with placebo (p=0.0311). Registry: NCT01639339 | 3 | Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104; Open-label Period: Number of Participants Reporting Adverse Events (AEs) and Serious AEs (SAEs) (From first open-label dose (Day 1) up to open-label Week 32 (8 weeks after last dose)); Open-label Period: Number of Participants Reporting Adverse Events of Special Interest (AESI) (From first open-label dose (Day 1) up to open-label Week 32 (8 weeks after last dose)) 2019-07-25 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT00071487 NCT00071487 · Systemic Lupus Erythematosus The trial was randomized and double-blind, used placebo plus standard therapy as the comparator, and enrolled 449 participants. Its primary clinical endpoints were not met: comparisons for disease-activity change and time to first flare were statistically non-significant for all three belimumab doses; no power calculation is reported in the provided sources. Registry: NCT00071487 | 2 | Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24. (Baseline, 24 weeks); Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index) (0 to 52 weeks) 2005-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
PLUTO NCT01649765 · Systemic Lupus Erythematosus The trial randomized 93 participants to belimumab (53) or placebo (40), with participants, care providers, investigators, and outcome assessors blinded. Its clinical primary endpoint, SRI response at Week 52, was not statistically significant (52.8% vs 43.6%; odds ratio 1.49, 95% CI 0.64–3.46), so the evidence is moderate rather than strong. Registry: NCT01649765 | 2 | Percentage of Participants With SLE Responder Index (SRI) Response at Week 52 2018-01-24 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
EMBRACE NCT01632241 · Systemic Lupus Erythematosus Registry: NCT01632241 | 4 | Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase]; Percentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL Phase (Week 24 of OL phase (Week 76)); Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Event (SAEs) [OL Phase] (Week 52 to Week 84); Number of Participants With Severe AEs [OL Phase] (Week 52 to Week 84); Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase] (Week 52 to Week 84); Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [OL Phase] (Week 52 to Week 84); Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [OL Phase] (Week 52 to Week 84); Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [OL Phase] (Week 52 to Week 84); Number of Participants With Worst Toxicity Grade of 3 or 4 of Immunoglobulins [OL Phase] (Week 52 to Week 84) 2018-06-18 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Competitive landscape
This drug's own stage for Lupus Nephritis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Belimumab (GSK1550188) (Benlysta): this drug | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | Reliable signal | No reviewed efficacy summary in this indication | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Voclosporin (Lupkynis) | Approved | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | Reliable signal | NCT03021499: Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%) | |
| Ebribafusp Alfa | Phase 2 | Protein / enzyme therapeutic | C3d / Factor H | not yet graded | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2 | Undisclosed | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2173 | Phase 2 | Undisclosed | IFNAR1 / TACI | not yet graded | No reviewed efficacy summary in this indication | |
| Vonsetamig | Phase 1 | — | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Benlysta (Belimumab (GSK1550188)) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.